---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-132585"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:55:49.001583+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Invivyd to pursue EUA for pemivibart for COVID-19 treatment in immunocompromised

## Summary
- Plans EUA submission for pemivibart to treat mild-to-moderate COVID-19 in moderately-to-severely immunocompromised people via immunobridging pathway.
- Immunobridging relies on Phase 2/3 STAMP trial data with adintrevimab and ongoing CANOPY trial for pemivibart PrEP.
- Manufacturing plan targets ~100,000 doses available through H2 2024 to serve both PrEP and potential treatment uses.
- 2024 net product revenue guidance remains $150-200M; year-end cash at least $75M, excluding potential treatment sales.
- After EUA submission, plans to initiate confirmatory safety, PK, and clinical virology trial.

## SEC filing metadata
- accession: 0001193125-24-132585
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000119312524132585/0001193125-24-132585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000119312524132585/d823090d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-132585
- JSON: https://secwatch.observer/filing/0001193125-24-132585.json
- Plain text: https://secwatch.observer/filing/0001193125-24-132585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.